Home  »  Business   »  Bristol-Myers Squibb Company (BMY) Is Sitting On A...

Bristol-Myers Squibb Company (BMY) Is Sitting On A Potential Gold Mine

Bristol-Myers Squibb Company (NYSE:BMY) at last check was buoying at $71.11 on Friday, September 23, with a fall of -0.26% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $71.29 and 5Y monthly beta was reading 0.42 with its price kept floating in the range of $69.20 and $71.875 on the day. Company’s P/E ratio for the trailing 12 months is 23.69. Considering stock’s 52-week price range provides that BMY hit a high price of $80.59 and saw its price falling to a low level of $53.22 during that period. Over a period of past 1-month, stock came subtracting -2.03% in its value.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

With its current market valuation of $152.78 billion, Bristol-Myers Squibb Company is set to declare its quarterly results on Oct 26, 2022. BMY Stock’s Forward Dividend of 2.16 and its yield of 3.03% are making investors’ thoughts stronger that it could climb further before the company announces its earnings for the current quarter. Analysts are in estimates of $1.84 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $7.51 for 2022 with estimates of that growing to $8.01 in next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $11.12 billion. They suggested that in the process company could generate revenue of as low as $10.81 billion which could climb up to $11.41 billion to hit a high. The average estimate is representing a decrease of -4.00% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $46.09 billion in 2022, which will be -0.60% less from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review BMY stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Sell for it.

According to ratings assigned by 21 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 8 of them are recommending Bristol-Myers Squibb Company (BMY) as a Hold, while 10 are in view that stock is a Buy. Recommendation by 1 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 1, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the BMY stock which is currently positioned at 5.10. It further provides that stock’s current price level is 1.83% away from its 20-day simple moving average and is -1.57% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 50.33 while volatility remained at 2.24% over the past week which changes to 2.26% when measuring it over the past month. Beta is valued at 0.41, while measure of average true range or ATR is currently at 1.71. In predicting price targets of as low as $61.00 and as high as $94.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $81.18. Stock’s current price level is 14.22% above from estimated low price target while it is -32.19% below the estimated high; and even if the BMY’s share succeeded to reach the median price of $84.00, then the outlook of -18.13% could come to the excitement of the investors.

In comparing Bristol-Myers Squibb Company (BMY)’s stock with other industry players reveals that stock’s latest price change of -0.26% and that of 18.52% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price raised by 0.59% in the recent trading and went through an increase of 1.37% in past 12-month trading. Industry’s another major player Pfizer Inc. (PFE) has fall -0.73% down in latest trading session, but over the past year has faced arise of 1.41%, while Abbott Laboratories (ABT) was also down -0.69% however its price remained floating in the red at -18.92% over the same period. Bristol-Myers Squibb Company has a P/E ratio of 23.69 against that of Johnson & Johnson’s 24.16 while Pfizer Inc. is showing 8.59 for the same. On the other hand, the S&P 500 Index is down -1.77% in the early deals today while the Dow Jones Industrial was dealinglower at -1.45%.

Having a second look at Bristol-Myers Squibb Company (NYSE:BMY) provides that stock’s average daily trading volume for 3 months was 9.75 million, while it jumped to 12.09 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 2.14 billion.

The percentage of outstanding shares held by the insiders is 0.07% while it is 79.80% for the institutional holders. The figures also indicate that as of Aug 30, 2022, number of stock’s short shares was 22.71 million which implies a short ratio of 2.61. This shows down a 1.06% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 27.83 million in the previous month. Addition of 14.34% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]